Translational risk remains a major challenge in obesity and kidney disease drug development. In obesity programs, reliance on body weight and food intake alone can obscure whether observed effects reflect true pharmacological efficacy or are driven by tolerability or other adverse effects. In kidney disease, conventional preclinical models may not fully reflect human pathology, limiting confidence in efficacy translation.

In this webinar, we will discuss how in-depth, patient-relevant in vivo phenotyping and advanced tissue analysis approaches can improve interpretation of preclinical efficacy signals and enable more robust candidate selection.

For obesity, we will explore how integrated in vivo profiling—including body composition imaging, energy expenditure, and rodent-compatible approaches to evaluate GLP-1-related emesis and muscle-related liabilities—can strengthen efficacy interpretation and support safer candidate selection. For kidney disease, we will highlight patient-relevant CKD models, including Axcelead's proprietary models for Alport syndrome and FSGS, and show how advanced tissue analysis approaches such as spatial transcriptomics, single-cell and single-nucleus analysis, and multiplex IHC can provide deeper insight into drug response within complex renal tissue.

Key topics:

• Strengthening anti-obesity efficacy assessment beyond body weight and food intake


• Early identification of GLP-1-related emesis and muscle-related liabilities


• Distinguishing true efficacy from adverse effect-driven signals through integrated MOA analysis


• Improving CKD efficacy evaluation using patient-relevant disease models


• Characterising renal drug responses through advanced tissue analysis approaches